Welcome To the Go-To Industry Forum for Pulmonary Fibrosis Professionals
The pulmonary fibrosis field is entering a pivotal moment. Boehringer Ingelheim’s positive Phase 3 trials for nerandomilast, poised to be the first new approval in over a decade, have injected long-awaited momentum into the space. PureTech Health, Endeavor BioMedicines, Insilico Medicine, Bristol Myers Squibb, and United Therapeutics are rapidly advancing through mid- to late-stage trials, signaling a renewed era of therapeutic possibility. Yet 2025 has also brought setbacks, including Pliant’s discontinuation of the BEACON-IPF study for bexotegrast due to safety concerns, underscoring the complexity of treating this disease.
If ever there was a year to invest in this space, it’s now. This August, meet your global community, spanning discovery, preclinical, translational, and clinical development, at the only industry-focused summit dedicated to pulmonary fibrosis. Gain the full spectrum of insight needed to bring better drugs to patients, faster.
Accomodation
We are pleased to announce that for the 9th IPF Summit we have a dedicated room block at the conference hotel, Hilton Boston Park Plaza.
We have a discounted nightly room rate of $279++ from Monday, August 18 to Wednesday, August 20.
World Renowned Speakers
Attending Companies Include









